Saudi VC firm Prosperity7 led investment of $35 million in Hong Kong firm

Prosperity7 Ventures, the growth fund of Saudi Aramco Ventures, has led a $35 million investment in Insilico Medicine, a Hong Kong-based AI-driven drug discovery company.

Based in Hong Kong with more than 200 employees, Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.Alex Zhavoronkov is its founder and CEO. (Prosperity7 is the diversified growth fund of Aramco Ventures, a subsidiary of Aramco, the Saudi energy and chemicals company, with $1 billion venture capital fund and a global investment strategy in all sectors)

Prosperity7 Ventures is listed in the Middle East Investors Directory with the code BJ96.